Invest in
Health care
£1,984,622
£2,500,000 *
£25.15 *
We’re Pure Medical, an early-stage health and wellness company that is seeking equity investment funding of £2.5m. We provide services that help patients stay healthy and out of the hospital. Our mission is to make high-quality innovative healthcare accessible and affordable to everyone.
PURE RESTORE HEALTH
* Company valuation by KPMG
- The Health & Wellness market was valued at £23bn in the UK in 2020
- 2022E and 2023E Projected revenue based on achievable and visible contract pipeline of ~£120M
We’re Pure Medical, an early-stage health and wellness company that is seeking equity investment funding of £2.5m. We provide services that help patients stay healthy and out of the hospital. Our mission is to make high-quality innovative healthcare accessible and affordable to everyone.
PURE RESTORE HEALTH
* Company valuation by KPMG
- The Health & Wellness market was valued at £23bn in the UK in 2020
- 2022E and 2023E Projected revenue based on achievable and visible contract pipeline of ~£120M
Unquoted UK equities
Access Pure Medical’s unquoted – unlisted – equities, and healthcare shares of a UK private limited company that are not traded on a recognised stock exchange, such as the London Stock Exchange.
Pure Medical has EIS and SEIS advance assurance from HMRC.
Target returns of £5.50 for each £1 invested.
Pay less. Access EIS fees are 52% lower than the industry average for EIS and VC funds.
Get 30p back in tax relief per £1 invested with EIS. Eligible investors only. Find out more.
Co-invest with the UK’s top-performing super angels.
Apply online or through your financial advisor.
Invest in Health Care
Pure Medical Share Prices
Pure Medical
Buy 100 Unquoted Unlisted UK Company Healthcare Shares
£25.15 per share
£2,515.00
Pure Medical
Buy 200 Unquoted Unlisted UK Company Healthcare Shares
£25.15 per share
£5,030.00
Pure Medical
Buy 400 Unquoted Unlisted UK Company Healthcare Shares
£25.15 per share
£10,060.00
Pure Medical
Buy 500 Unquoted Unlisted UK Company Healthcare Shares
£25.15 per share
£12,575.00
Pure Medical
Buy 600 Unquoted Unlisted UK Company Healthcare Shares
£25.15 per share
£15,090.00
Pure Medical
Buy 1000 Unquoted Unlisted UK Company Healthcare Shares
£25.15 per share
£25,150.00
For larger quantity purchases please contact Pure Medical investment team at investors@pure-medical.co.uk
THE OPPORTUNITY
Pain and Ageing are universal problems. Pure Medical utilizes the latest in healthcare technologies and proactive wellness services to help people feel their best.
Pure Restore Health
THE PROBLEM & THE SOLUTION
Pure Medical
Healthcare Investment
Pure Medical’s Offering
We offer a broad spectrum of innovative health services
You can consult with a
clinician whenever you like
Take control of your health and wellness
A better way to track wellness
£2.5M
Offer for subscription to raise £2.5 million to fund Equity for Health (subject to increase at the discretion of the Directors to no more than £50 million).
£23 Billion
The Health & Wellness market was valued at £23bn in the UK in 2020¹ | CAGR: 8.8% | Pure Medical is well-positioned in that it has the competitive advantage of being first to market in the UK.
~£120M Contract Pipeline
Path to 2022E and 2023E Projected Revenue Based on Achievable and Visible Contract Pipeline of ~£120M¹ with Upside Potential
UK £25.15
New Shares will be issued at a price of £25.15 per share with a minimum subscription of two shares in Equity for Health, the opportunity to purchase unlisted shares in the fastest growing technical healthcare provider.
Class B Shares pre-emption right
For every share purchased in this round, investors also receive a pre-emption right to (at their option) purchase an additional share of common stock at £25.15 per share in the company’s next fundraising round.
Invest in Healthcare
More Info on the
Class B PRE-EMPTION RIGHTS
Invest in Healthcare
Partners & Customers Including:
Who We Are
Executive Management and Board
“With all the advancements in science, medicine, and technology, we, as humans, are capable of so much more, living better lives with increased levels of vitality, above and beyond what we have ever experienced. Our goal is to bring these advancements to as many people as possible.”
Gary brings over 25 years of executive board experience running high growth companies experiencing significant scale. Gary is a founding member of Pure Medical. Most recently, he served as Managing Director at HTTC Healthcare – Poseidonia where he spent 2 years. Gary continues to serve on the Executive Board of a global biopharmaceutical group. In his role at HTTC Healthcare, Gary was responsible for strategic and financial planning, financial accounting, and global team leadership.
Dr John Howe MBBS BSc MRCGP graduated from Imperial College London, obtaining dual degrees in both Medicine and Healthcare Management. Dr Howe completed post-graduate training in the United Kingdom and Australia, specializing in General Practice. After a three-year period serving as a cruise ship physician, Dr Howe successfully ran his own clinic in Kazakhstan.
Most recently Dr Howe served as Chief Medical Officer to an Estonian telemedicine platform as the company prepared to launch its platform to six million patients in India. There, he led doctor recruitment and set the standards in clinical quality assurance.
Dr Anna Davidsson is a highly qualified physician with more than ten years of expertise. She has worked as a doctor in both the United Kingdom and Iceland. She is well-positioned to support Pure Medical’s expansion objectives, as she has substantial managerial expertise.
Dr David Yakobi is a Board-Certified Cardiac Surgeon and specialist in Cardiology, Intensive Care, Emergency Medicine, Hemodynamics, and Physiology. Dr Yakobi has vast experience in Coronary Artery Disease, Valvular disease, and Paediatric congenital heart disease.
Dale brings with him over 20 years of experience running operational teams at high growth companies experiencing significant scale. Dale co-founded Pure Medical previously holding positions at HTTC Medical – Poseidonia Healthcare, where he spent 2 years and served on the UK Board of Directors. Dale continues to serve on the executive board of the global biopharmaceutical company.